Clinical trials: Hepatitis C, completed
Hepatitis C
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
A single-arm, multi-center study of HCV-1b patients without baseline non-structure protein (NS5A) resistance-associated variants.
- Trial name
- NCT03004625
- Testing
- daclatasvir, asunaprevir, Ribavirin
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Chronic Hepatitis C Infection
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are…
- Trial name
- SWITCH-1 (NCT02583685)
- Testing
- PR4 + LDV/SOF + ASV 4 wk, PR4 + LDV/SOF + SMV 4 wk, PR4 + LDV/SOF + ASV 6 wk
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Humanity and Health Research Centre
Hepatitis C
Plasma MicroRNA for Prediction of Hepatocellular Carcinoma
100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78).
- Trial name
- NCT05449847
- Testing
- Blood Sampling
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Benha University
Hepatitis C, Chronic
KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C
This study aimed to confirm efficacy and safety of KW-136, an investigational anti-hepatitis C virus (HCV) drug, combined with sofosbuvir for treatment of naive and experienced adults chronically infected with HCV.
- Trial name
- KW-136_III (NCT03995485)
- Testing
- KW-136 capsule, Sofosbuvir
- Where
- 19 sites in China
- Volunteers
- 371 people
- Sponsor
- Kawin Technology Share-holding Co., Ltd.
Chronic Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
The purpose of this study is to evaluate the safety and efficacy of a quadruple regimen (VX-222, telaprevir, pegylated interferon, and ribavirin)in subjects with hepatitis C with cirrhosis.
- Trial name
- NCT01516918
- Testing
- VX-222, telaprevir, ribavirin
- Where
- 43 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)
The purpose of this study is to assess the safety and antiviral activity of IDX184 in combination with pegylated interferon and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT01371604
- Testing
- IDX184, Peginterferon alfa-2a (Peg-IFN), Ribavirin (RBV)
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection
To evaluate the safety, tolerability and immunogenicity of VGX-6150 as second-line therapy in chronic hepatitis C patients
- Trial name
- VGX-6150-01 (NCT02027116)
- Testing
- VGX-6150
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- GeneOne Life Science, Inc.
Hepatitis C, Chronic
A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants
The purpose of this study is to determine the efficacy of a 12- or 24-week treatment regimen of simeprevir in combination with daclatasvir, as measured by sustain virologic response 12 (SVR12), in treatment-naive, chronic…
- Trial name
- COMMIT (NCT02268864)
- Testing
- Simeprevir, Daclatasvir
- Where
- 23 sites in Belgium, France and 4 more
- Volunteers
- 106 people
- Sponsor
- Janssen-Cilag International NV
Hepatitis C, Chronic
Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)
Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695)
- Trial name
- NCT01081158
- Testing
- Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron), Drug: SCH 900518 Biologic: Peginterferon alfa-2b, Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, HIV Infections
Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients
This study will evaluate the safety and effectiveness of combination therapy with peginterferon alpha-2a and ribavirin for treating hepatitis C virus (HCV) infection in HIV-infected patients.
- Trial name
- PIFNPK (NCT00085917)
- Testing
- Double dose pegylated interferon with weight based Ribavirin, standard dose pegylated interferon alfa -2a and ribavirin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis C Infection
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
The study is designed to provide long term clinical and virologic follow up in subjects infected with hepatitis C virus (HCV) who received interferon-based therapy or direct-acting antiviral agents (DAAs)-based therapy.
- Trial name
- NCT02578693
- Where
- 3 sites in China, Japan
- Volunteers
- 1,210 people
- Sponsor
- Humanity and Health Research Centre
Hepatitis C and HIV Coinfection
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir
This study evaluates the effect of sofosbuvir/ledipasvir (SOF/LDV) treatment on the pharmacokinetics (PK) and renal safety of tenofovir.
- Trial name
- NCT02588287
- Testing
- Blood draws for tenofovir PK, renal function
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Colorado, Denver
Hepatitis C
Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B
Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not…
- Trial name
- NCT01429155
- Testing
- Interleukin 28B genotype
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Henry Ford Health System
Hepatitis C
Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
The primary objective of this study is to describe the safety of the combination of Daklinza (daclatasvir) and Sunvepra (asunaprevir) when used for the treatment of chronic hepatitis C (CHC) genotype 1b patients in real-life…
- Trial name
- NCT02727933
- Where
- South Korea
- Volunteers
- 1,941 people
- Sponsor
- Bristol-Myers Squibb
HCV Infection
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
Hepatitis C virus (HCV) is an enveloped, single strand, positive sense RNA flavivirus. Infection by HCV is typically chronic, although an estimated ~10-20% may spontaneously clear the virus.
- Trial name
- NCT03674125
- Testing
- GLS-6150
- Where
- 2 sites in South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Hepatitis C, Chronic
A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1
The purpose of the study is to evaluate the efficacy and safety of Albuferon in combination with ribavirin in interferon (IFN) alfa treatment-naïve subjects with chronic hepatitis C genotype 1.
- Trial name
- NCT00115908
- Testing
- Albuferon, Ribavirin, PEG-IFNalfa2a
- Where
- 87 sites in Australia, Canada and 6 more
- Volunteers
- 458 people
- Sponsor
- Human Genome Sciences Inc.
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis…
- Trial name
- ASTRAL-1 (NCT02201940)
- Testing
- SOF/VEL
- Where
- 80 sites in United States, Belgium and 7 more
- Volunteers
- 741 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- NCT02798315
- Volunteers
- 40 people
- Sponsor
- AbbVie
Hepatitis C Virus Infection
Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
This post-marketing surveillance (PMS) study for Sovaldi® tablets (sofosbuvir, SOF) administered in combination with Copegus® tablets (ribavirin, COPE) will evaluate the safety and efficacy of SOF administered in combination with…
- Trial name
- NCT02537379
- Testing
- SOF, COPE
- Where
- 45 sites in Japan
- Volunteers
- 552 people
- Sponsor
- Gilead Sciences
Hepatitis C
EPIC: Evaluation of Pharmacy-based Identification and Treatment of HCV
The research project aims to understand how pharmacies can be involved in the identification and treatment of hepatitis C (hep C).
- Trial name
- EPIC (NCT05412017)
- Testing
- Hepatitis C Point of Care Testing and Treatment
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Cool Aid Community Health Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.